<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00249769</url>
  </required_header>
  <id_info>
    <org_study_id>JEV01</org_study_id>
    <nct_id>NCT00249769</nct_id>
  </id_info>
  <brief_title>Determining Safety and Efficacy of Japanese Encephalitis Vaccine When Given With Measles Vaccine</brief_title>
  <official_title>Assessment of the Non-Inferiority of the Concurrent Administration of Japanese Encephalitis Live Attenuated SA 14-14-2 Vaccine and Measles Vaccine Given Alone</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>PATH</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Research Institute for Tropical Medicine, Manila, Philippines</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Quintiles, Inc.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>Mahidol University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>PATH</source>
  <brief_summary>
    <textblock>
      This study will determine whether it is safe and effective to administer Japanese
      encephalitis (JE) live attenuated SA 14-14-2 vaccine at the same time as measles vaccine. If
      it is found to be safe, it will pave the way for use in routine vaccination programs. The
      hypothesis is that children who receive JE live attenuated SA 14-14-2 vaccine and measles
      vaccine at the same time are protected against these diseases at the same level as those who
      receive the vaccines at different intervals.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Japanese encephalitis is the leading cause of viral neurological disease and disability in
      Asia. The severity of sequelae, together with the volume of cases, make JE the most important
      cause of viral encephalitis in the world. Approximately 3 billion people—including 700
      million children—live in Asian areas at risk for JE. JE most commonly infects children
      between the ages of 1 and 15 years, and can also infect adults in areas where the virus is
      newly introduced. More than 50,000 cases are reported annually and cause an estimated 10,000
      to 15,000 deaths. This figure is believed to represent only a small proportion of the disease
      burden that actually exists.

      An effective vaccine has existed since 1941, but has not reached the poorest countries in
      Asia. During the 60 years that the vaccine has been available, JE has infected an estimated
      10.5 million children, resulting in more than 3 million deaths and more than 4 million
      children living with long-term disabilities. Control of this disease has been limited due to
      poor disease surveillance, a limited and unstable vaccine supply, lack of guidance and
      programmatic support for immunization, and limited advocacy.

      A successful vaccine should be safe, efficacious, affordable, administered in a single dose,
      and easily incorporated into the routine Expanded Programmes on Immunization (EPI) programs.
      This study will help ensure the safety of SA 14-14-2 simultaneously administered with measles
      vaccine, paving the way for its use in routine EPI programs. If this candidate becomes widely
      available, it will drastically increase the feasibility of routine JE immunization in Asia,
      reducing the devastating death and disability caused by this disease. In addition to
      impacting low-income countries, the vaccine will allow countries that purchase vaccine—such
      as Thailand, Vietnam, Sri Lanka, and India—to recover health care dollars, improve their
      present programs, and address other unmet health care needs.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">November 21, 2005</start_date>
  <completion_date type="Actual">May 30, 2006</completion_date>
  <primary_completion_date type="Actual">May 30, 2006</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Percentage of Participants With Seroprotection for Measles 4 Weeks After Vaccination</measure>
    <time_frame>Day 0 (before vaccination) and Day 28 (4 weeks after measles vaccination)</time_frame>
    <description>Seroprotection after measles vaccination was defined as a measles antibody titer ≥ 120 mIU/mL. Measles immunoglobulin G (IgG) antibody was determined using the Enzygnost® Anti-Measles Virus/IgG enzyme-linked immunosorbent assay(ELISA) assay from Siemens, Marburg, Germany.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With Seroprotection for Japanese Encephalitis 4 Weeks After Vaccination</measure>
    <time_frame>Day 0 (before vaccination) and Day 28 (4 weeks after LJEV vaccination)</time_frame>
    <description>Seroprotection after LJEV was defined as at least 1:10 dilution as recommended by the World Health Organization (WHO). JE antibody titers were determined by a plaque reduction neutralization test (PRNT).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Geometric Mean Concentration (GMC) of Measles Antibodies After Vaccination</measure>
    <time_frame>Day 0 (before vaccination) and Day 28 (4 weeks after measles vaccination)</time_frame>
    <description>Measured using the Enzygnost® Anti-Measles Virus/IgG ELISA assay from Siemens, Marburg, Germany.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Geometric Mean Titer (GMT) of Japanese Encephalitis Antibodies After Vaccination</measure>
    <time_frame>Day 0 (before vaccination) and Day 28 (4 weeks after LJEV vaccination)</time_frame>
    <description>Assayed by plaque reduction neutralization test (PRNT).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants Experiencing Local and Systemic Reactogenicity After Receiving Live Attenuated Japanese Encephalitis Vaccine (LJEV)</measure>
    <time_frame>Up to 7 days after LJEV administration</time_frame>
    <description>Local reactions included erythema, pain, swelling, or induration. Systemic reactions included loss of appetite, crying, diarrhea, drowsiness, insomnia, irritability, vomiting, or fever. The parents of the participants recorded all local reactions and systemic events on an individual safety diary form.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants Experiencing Local and Systemic Reactogenicity After Receiving Measles Vaccine</measure>
    <time_frame>Up to 7 days after measles vaccination</time_frame>
    <description>Local reactions included erythema, pain, swelling, and induration. Systemic reactions included loss of appetite, crying, diarrhea, drowsiness, insomnia, irritability, and vomiting. The parents of the participants recorded all local reactions and systemic events on an individual safety diary form.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants Experiencing Unsolicited Adverse Events (AE)</measure>
    <time_frame>Up to 7 days post-vaccination</time_frame>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">600</enrollment>
  <condition>Encephalitis, Japanese B</condition>
  <arm_group>
    <arm_group_label>LJEV then MV</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Received one dose of Live Japanese encephalitis vaccine SA 14-14-2 (LJEV) at 8 months of age, and one dose of measles vaccine (MV) one month later.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>LJEV and MV</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Received one dose of Live Japanese encephalitis vaccine SA 14-14-2 (LJEV) concurrently with one dose of measles vaccine (MV) at 9 months of age.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>MV then LJEV</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Received one dose of measles vaccine (MV) at 9 months of age, followed by one dose of Live Japanese encephalitis vaccine SA 14-14-2 (LJEV) one month later.</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Live Japanese encephalitis vaccine SA 14-14-2 (LJEV)</intervention_name>
    <description>Live Japanese encephalitis vaccine SA 14-14-2 (LJEV) is lyophilized powder that looks like a milky-white crisp cake. After reconstitution, it turns into a transparent orange red liquid. Its container is a vial. It is stored and transported between 2°C to 8°C and protected from light. Each single human dose is 0.5 ml containing not less than 5.4 log particle flux unit (PFU) of live Japanese Encephalitis (JE) virus. The 0.5ml injection is delivered subcutaneously via auto-disable syringe. Lot number 200411129-3 manufactured by Chengdu Institute of Biological Products (CDIBP), Chengdu, China.</description>
    <arm_group_label>LJEV and MV</arm_group_label>
    <arm_group_label>LJEV then MV</arm_group_label>
    <arm_group_label>MV then LJEV</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Measles Vaccine (MV)</intervention_name>
    <description>The Serum Institute of India (SII) measles vaccine provided routinely in the Expanded Program on Immunization (EPI) of the Philippines was the measles vaccine provided to the study participants. The vaccine met the requirements of the World Health Organization (WHO).
SII measles vaccine contained live attenuated (freeze-dried) Edmonston-Zagreb strain measles virus propagated on human diploid cells (HDC). Each single human dose when reconstituted in a volume of 0.5 ml contains no less than 1000 Cell culture infectious dose 50% (CCID50) of live virus particles. SII measles vaccine is presented as a yellowish-white dry cake. The vaccine should be reconstituted with the diluent supplied (sterile water for injection). A sterile disposable syringe and needle are supplied separately. The 0.5ml injection is delivered subcutaneously via auto-disable syringe. Lot number 2979.</description>
    <arm_group_label>LJEV and MV</arm_group_label>
    <arm_group_label>LJEV then MV</arm_group_label>
    <arm_group_label>MV then LJEV</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Participant is healthy, aged between 8 months (± 2 weeks) at inclusion visit

          -  Subject is a full-term infant

          -  Subject's parents or legal guardian willing to provide signed informed consent.

          -  Children have completed 3 doses each of diphtheria, tetanus, pertussis (DTP) and oral
             polio vaccine (OPV).

        Exclusion Criteria:

          -  History of documented HIV.

          -  Known or suspected impairment of immunologic function.

          -  History of serious chronic disease

          -  Underlying medical condition such as inborn errors of metabolism, failure to thrive,
             bronchopulmonary dysplasia, or any major congenital abnormalities requiring surgery or
             chronic treatment.

          -  Acute medical illness with or without fever within the last 72 hours or an axillary
             temperature ≥ 37.5°C at the time of inclusion.

          -  History of documented suspected encephalitis, encephalopathy, or meningitis

          -  History of measles

          -  History of thrombocytopenic purpura.

          -  Received any JE or measles vaccine prior to enrollment.

          -  Received any vaccine, other than the study vaccines, within 2 weeks prior to or
             scheduled to receive a non-study vaccination during the conduct of this trial.

          -  Hypotonic - hyporesponsiveness, after the preceding vaccination.

          -  History of seizures, including history of febrile seizures, or any other neurologic
             disorder.

          -  Prior or anticipated receipt of immune globulin or other blood products, or injected
             or oral corticosteroids or other immune modulator therapy except routine vaccines
             within 6 weeks of administration of the study vaccines. Individuals on a tapering dose
             schedule of oral steroids lasting &lt;7 days may be included in the trial as long as they
             have not received more than one course within the last 2 weeks prior to enrollment.

          -  Suspected or known hypersensitivity to any of the investigational or marketed vaccine
             components.

          -  Serious adverse event related to the vaccine (i.e., possible, probably, definite)

          -  Persistent inconsolable crying (&gt;3 hours) observed after a previous dose.

          -  Unable to attend the scheduled visits or comply with the study procedures.

          -  Enrolled in another clinical trial involving any therapy.

          -  Any condition that in the opinion of the investigator, would pose a health risk to the
             participant, or interfere with the evaluation of the study objectives.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>8 Months</minimum_age>
    <maximum_age>11 Months</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Salvacion Gatchalian, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Research Institute for Tropical Medicine,</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Research Institute for Tropical Medicine</name>
      <address>
        <city>Manila</city>
        <country>Philippines</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Philippines</country>
  </location_countries>
  <results_reference>
    <citation>Gatchalian S, Yao Y, Zhou B, Zhang L, Yoksan S, Kelly K, Neuzil KM, Yaïch M, Jacobson J. Comparison of the immunogenicity and safety of measles vaccine administered alone or with live, attenuated Japanese encephalitis SA 14-14-2 vaccine in Philippine infants. Vaccine. 2008 Apr 24;26(18):2234-41. doi: 10.1016/j.vaccine.2008.02.042. Epub 2008 Mar 18.</citation>
    <PMID>18394765</PMID>
  </results_reference>
  <verification_date>September 2018</verification_date>
  <study_first_submitted>November 3, 2005</study_first_submitted>
  <study_first_submitted_qc>November 3, 2005</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 7, 2005</study_first_posted>
  <results_first_submitted>September 8, 2018</results_first_submitted>
  <results_first_submitted_qc>February 25, 2020</results_first_submitted_qc>
  <results_first_posted type="Actual">March 10, 2020</results_first_posted>
  <last_update_submitted>February 25, 2020</last_update_submitted>
  <last_update_submitted_qc>February 25, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">March 10, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Japanese Encephalitis</keyword>
  <keyword>Japanese B Encephalitis</keyword>
  <keyword>Japanese B Viral Encephalitis</keyword>
  <keyword>Viral Encephalitis, Japanese B</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Encephalitis, Japanese</mesh_term>
    <mesh_term>Encephalitis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vaccines</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>LJEV Then MV</title>
          <description>Received one dose of Live Japanese encephalitis vaccine SA 14-14-2 (LJEV) at 8 months of age, and one dose of measles vaccine (MV) one month later.</description>
        </group>
        <group group_id="P2">
          <title>LJEV and MV</title>
          <description>Received one dose of Live Japanese encephalitis vaccine SA 14-14-2 (LJEV) concurrently with one dose of measles vaccine (MV) at 9 months of age.</description>
        </group>
        <group group_id="P3">
          <title>MV Then LJEV</title>
          <description>Received one dose of measles vaccine (MV) at 9 months of age, followed by one dose of Live Japanese encephalitis vaccine SA 14-14-2 (LJEV) one month later.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="100"/>
                <participants group_id="P2" count="250"/>
                <participants group_id="P3" count="250"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Received LJEV</title>
              <participants_list>
                <participants group_id="P1" count="100"/>
                <participants group_id="P2" count="236"/>
                <participants group_id="P3" count="224"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Received Measles Vaccine</title>
              <participants_list>
                <participants group_id="P1" count="97"/>
                <participants group_id="P2" count="236"/>
                <participants group_id="P3" count="235"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="98"/>
                <participants group_id="P2" count="235"/>
                <participants group_id="P3" count="222"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="15"/>
                <participants group_id="P3" count="28"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="10"/>
                <participants group_id="P3" count="6"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Migration from Study Area</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="3"/>
                <participants group_id="P3" count="14"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Miscellaneous</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="2"/>
                <participants group_id="P3" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Physician Decision</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="3"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>The Safety population included all participants who received at least 1 vaccination.</population>
      <group_list>
        <group group_id="B1">
          <title>LJEV Then MV</title>
          <description>Received one dose of Live Japanese encephalitis vaccine SA 14-14-2 (LJEV) at 8 months of age, and one dose of measles vaccine (MV) one month later.</description>
        </group>
        <group group_id="B2">
          <title>LJEV and MV</title>
          <description>Received one dose of Live Japanese encephalitis vaccine SA 14-14-2 (LJEV) concurrently with one dose of measles vaccine (MV) at 9 months of age.</description>
        </group>
        <group group_id="B3">
          <title>MV Then LJEV</title>
          <description>Received one dose of measles vaccine (MV) at 9 months of age, followed by one dose of Live Japanese encephalitis vaccine SA 14-14-2 (LJEV) one month later.</description>
        </group>
        <group group_id="B4">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="100"/>
            <count group_id="B2" value="236"/>
            <count group_id="B3" value="235"/>
            <count group_id="B4" value="571"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>months</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="7.9" spread="0.3"/>
                    <measurement group_id="B2" value="8.9" spread="0.3"/>
                    <measurement group_id="B3" value="8.9" spread="0.3"/>
                    <measurement group_id="B4" value="8.7" spread="0.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="48"/>
                    <measurement group_id="B2" value="108"/>
                    <measurement group_id="B3" value="128"/>
                    <measurement group_id="B4" value="284"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="52"/>
                    <measurement group_id="B2" value="128"/>
                    <measurement group_id="B3" value="107"/>
                    <measurement group_id="B4" value="287"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Weight</title>
          <units>kilograms</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="7.9" spread="1.0"/>
                    <measurement group_id="B2" value="8.0" spread="1.0"/>
                    <measurement group_id="B3" value="8.1" spread="1.0"/>
                    <measurement group_id="B4" value="8.0" spread="1.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Height</title>
          <units>centimeters</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="66.3" spread="2.6"/>
                    <measurement group_id="B2" value="67.6" spread="2.7"/>
                    <measurement group_id="B3" value="67.7" spread="2.6"/>
                    <measurement group_id="B4" value="67.4" spread="2.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Percentage of Participants With Seroprotection for Measles 4 Weeks After Vaccination</title>
        <description>Seroprotection after measles vaccination was defined as a measles antibody titer ≥ 120 mIU/mL. Measles immunoglobulin G (IgG) antibody was determined using the Enzygnost® Anti-Measles Virus/IgG enzyme-linked immunosorbent assay(ELISA) assay from Siemens, Marburg, Germany.</description>
        <time_frame>Day 0 (before vaccination) and Day 28 (4 weeks after measles vaccination)</time_frame>
        <population>The per-protocol population includes randomized participants who received at least one vaccine dose excluding participants who did not meet the inclusion/exclusion criteria or were found non-compliant to the immunization or blood sampling schedule. The analysis includes participants with valid serology results for measles antibody during retesting.</population>
        <group_list>
          <group group_id="O1">
            <title>LJEV Then MV</title>
            <description>Received one dose of Live Japanese encephalitis vaccine SA 14-14-2 (LJEV) at 8 months of age, and one dose of measles vaccine (MV) one month later.</description>
          </group>
          <group group_id="O2">
            <title>LJEV and MV</title>
            <description>Received one dose of Live Japanese encephalitis vaccine SA 14-14-2 (LJEV) concurrently with one dose of measles vaccine (MV) at 9 months of age.</description>
          </group>
          <group group_id="O3">
            <title>MV Then LJEV</title>
            <description>Received one dose of measles vaccine (MV) at 9 months of age, followed by one dose of Live Japanese encephalitis vaccine SA 14-14-2 (LJEV) one month later.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With Seroprotection for Measles 4 Weeks After Vaccination</title>
          <description>Seroprotection after measles vaccination was defined as a measles antibody titer ≥ 120 mIU/mL. Measles immunoglobulin G (IgG) antibody was determined using the Enzygnost® Anti-Measles Virus/IgG enzyme-linked immunosorbent assay(ELISA) assay from Siemens, Marburg, Germany.</description>
          <population>The per-protocol population includes randomized participants who received at least one vaccine dose excluding participants who did not meet the inclusion/exclusion criteria or were found non-compliant to the immunization or blood sampling schedule. The analysis includes participants with valid serology results for measles antibody during retesting.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="88"/>
                <count group_id="O2" value="219"/>
                <count group_id="O3" value="178"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Day 0</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.1" lower_limit="0.0" upper_limit="6.2"/>
                    <measurement group_id="O2" value="0.0" lower_limit="0.0" upper_limit="1.7"/>
                    <measurement group_id="O3" value="0.0" lower_limit="0.0" upper_limit="2.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 28</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="88.6" lower_limit="80.1" upper_limit="94.4"/>
                    <measurement group_id="O2" value="91.8" lower_limit="87.3" upper_limit="95.1"/>
                    <measurement group_id="O3" value="86.5" lower_limit="80.6" upper_limit="91.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants With Seroprotection for Japanese Encephalitis 4 Weeks After Vaccination</title>
        <description>Seroprotection after LJEV was defined as at least 1:10 dilution as recommended by the World Health Organization (WHO). JE antibody titers were determined by a plaque reduction neutralization test (PRNT).</description>
        <time_frame>Day 0 (before vaccination) and Day 28 (4 weeks after LJEV vaccination)</time_frame>
        <population>Per protocol population</population>
        <group_list>
          <group group_id="O1">
            <title>LJEV Then MV</title>
            <description>Received one dose of Live Japanese encephalitis vaccine SA 14-14-2 (LJEV) at 8 months of age, and one dose of measles vaccine (MV) one month later.</description>
          </group>
          <group group_id="O2">
            <title>LJEV and MV</title>
            <description>Received one dose of Live Japanese encephalitis vaccine SA 14-14-2 (LJEV) concurrently with one dose of measles vaccine (MV) at 9 months of age.</description>
          </group>
          <group group_id="O3">
            <title>MV Then LJEV</title>
            <description>Received one dose of measles vaccine (MV) at 9 months of age, followed by one dose of Live Japanese encephalitis vaccine SA 14-14-2 (LJEV) one month later.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With Seroprotection for Japanese Encephalitis 4 Weeks After Vaccination</title>
          <description>Seroprotection after LJEV was defined as at least 1:10 dilution as recommended by the World Health Organization (WHO). JE antibody titers were determined by a plaque reduction neutralization test (PRNT).</description>
          <population>Per protocol population</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="88"/>
                <count group_id="O2" value="222"/>
                <count group_id="O3" value="180"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Day 0</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.4" lower_limit="0.7" upper_limit="9.6"/>
                    <measurement group_id="O2" value="5.4" lower_limit="2.8" upper_limit="9.3"/>
                    <measurement group_id="O3" value="6.1" lower_limit="3.1" upper_limit="10.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 28</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="92.1" lower_limit="84.3" upper_limit="96.7"/>
                    <measurement group_id="O2" value="90.5" lower_limit="85.9" upper_limit="94.1"/>
                    <measurement group_id="O3" value="90.6" lower_limit="85.3" upper_limit="94.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Geometric Mean Concentration (GMC) of Measles Antibodies After Vaccination</title>
        <description>Measured using the Enzygnost® Anti-Measles Virus/IgG ELISA assay from Siemens, Marburg, Germany.</description>
        <time_frame>Day 0 (before vaccination) and Day 28 (4 weeks after measles vaccination)</time_frame>
        <population>Per-protocol population; the analysis includes participants with valid serology results for measles antibody during retesting.</population>
        <group_list>
          <group group_id="O1">
            <title>LJEV Then MV</title>
            <description>Received one dose of Live Japanese encephalitis vaccine SA 14-14-2 (LJEV) at 8 months of age, and one dose of measles vaccine (MV) one month later.</description>
          </group>
          <group group_id="O2">
            <title>LJEV and MV</title>
            <description>Received one dose of Live Japanese encephalitis vaccine SA 14-14-2 (LJEV) concurrently with one dose of measles vaccine (MV) at 9 months of age.</description>
          </group>
          <group group_id="O3">
            <title>MV Then LJEV</title>
            <description>Received one dose of measles vaccine (MV) at 9 months of age, followed by one dose of Live Japanese encephalitis vaccine SA 14-14-2 (LJEV) one month later.</description>
          </group>
        </group_list>
        <measure>
          <title>Geometric Mean Concentration (GMC) of Measles Antibodies After Vaccination</title>
          <description>Measured using the Enzygnost® Anti-Measles Virus/IgG ELISA assay from Siemens, Marburg, Germany.</description>
          <population>Per-protocol population; the analysis includes participants with valid serology results for measles antibody during retesting.</population>
          <units>mIU/mL</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="88"/>
                <count group_id="O2" value="219"/>
                <count group_id="O3" value="178"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Day 0</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="12.8" lower_limit="10.2" upper_limit="16.2"/>
                    <measurement group_id="O2" value="7.4" lower_limit="6.3" upper_limit="8.8"/>
                    <measurement group_id="O3" value="7.0" lower_limit="5.8" upper_limit="8.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 28</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="318.9" lower_limit="273.0" upper_limit="372.6"/>
                    <measurement group_id="O2" value="301.9" lower_limit="269.0" upper_limit="338.9"/>
                    <measurement group_id="O3" value="262.5" lower_limit="222.2" upper_limit="310.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Geometric Mean Titer (GMT) of Japanese Encephalitis Antibodies After Vaccination</title>
        <description>Assayed by plaque reduction neutralization test (PRNT).</description>
        <time_frame>Day 0 (before vaccination) and Day 28 (4 weeks after LJEV vaccination)</time_frame>
        <population>Per-protocol population</population>
        <group_list>
          <group group_id="O1">
            <title>LJEV Then MV</title>
            <description>Received one dose of Live Japanese encephalitis vaccine SA 14-14-2 (LJEV) at 8 months of age, and one dose of measles vaccine (MV) one month later.</description>
          </group>
          <group group_id="O2">
            <title>LJEV and MV</title>
            <description>Received one dose of Live Japanese encephalitis vaccine SA 14-14-2 (LJEV) concurrently with one dose of measles vaccine (MV) at 9 months of age.</description>
          </group>
          <group group_id="O3">
            <title>MV Then LJEV</title>
            <description>Received one dose of measles vaccine (MV) at 9 months of age, followed by one dose of Live Japanese encephalitis vaccine SA 14-14-2 (LJEV) one month later.</description>
          </group>
        </group_list>
        <measure>
          <title>Geometric Mean Titer (GMT) of Japanese Encephalitis Antibodies After Vaccination</title>
          <description>Assayed by plaque reduction neutralization test (PRNT).</description>
          <population>Per-protocol population</population>
          <units>titer</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="88"/>
                <count group_id="O2" value="219"/>
                <count group_id="O3" value="178"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Day 0</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.7" lower_limit="4.9" upper_limit="6.5"/>
                    <measurement group_id="O2" value="5.7" lower_limit="5.2" upper_limit="6.1"/>
                    <measurement group_id="O3" value="5.9" lower_limit="5.3" upper_limit="6.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 28</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="202.8" lower_limit="140.5" upper_limit="292.9"/>
                    <measurement group_id="O2" value="155.0" lower_limit="123.5" upper_limit="194.5"/>
                    <measurement group_id="O3" value="139.4" lower_limit="109.5" upper_limit="177.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants Experiencing Local and Systemic Reactogenicity After Receiving Live Attenuated Japanese Encephalitis Vaccine (LJEV)</title>
        <description>Local reactions included erythema, pain, swelling, or induration. Systemic reactions included loss of appetite, crying, diarrhea, drowsiness, insomnia, irritability, vomiting, or fever. The parents of the participants recorded all local reactions and systemic events on an individual safety diary form.</description>
        <time_frame>Up to 7 days after LJEV administration</time_frame>
        <population>Participants who received LJEV</population>
        <group_list>
          <group group_id="O1">
            <title>LJEV Then MV</title>
            <description>Received one dose of Live Japanese encephalitis vaccine SA 14-14-2 (LJEV) at 8 months of age, and one dose of measles vaccine (MV) one month later.</description>
          </group>
          <group group_id="O2">
            <title>LJEV and MV</title>
            <description>Received one dose of Live Japanese encephalitis vaccine SA 14-14-2 (LJEV) concurrently with one dose of measles vaccine (MV) at 9 months of age.</description>
          </group>
          <group group_id="O3">
            <title>MV Then LJEV</title>
            <description>Received one dose of measles vaccine (MV) at 9 months of age, followed by one dose of Live Japanese encephalitis vaccine SA 14-14-2 (LJEV) one month later.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants Experiencing Local and Systemic Reactogenicity After Receiving Live Attenuated Japanese Encephalitis Vaccine (LJEV)</title>
          <description>Local reactions included erythema, pain, swelling, or induration. Systemic reactions included loss of appetite, crying, diarrhea, drowsiness, insomnia, irritability, vomiting, or fever. The parents of the participants recorded all local reactions and systemic events on an individual safety diary form.</description>
          <population>Participants who received LJEV</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="100"/>
                <count group_id="O2" value="236"/>
                <count group_id="O3" value="224"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Local reactions: any</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="27"/>
                    <measurement group_id="O2" value="53"/>
                    <measurement group_id="O3" value="27"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Local reactions: mild</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="19"/>
                    <measurement group_id="O2" value="48"/>
                    <measurement group_id="O3" value="22"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Local reactions: moderate</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8"/>
                    <measurement group_id="O2" value="5"/>
                    <measurement group_id="O3" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Local reactions: severe</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Systemic reactions: any</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="58"/>
                    <measurement group_id="O2" value="97"/>
                    <measurement group_id="O3" value="88"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Systemic reaction: mild</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="34"/>
                    <measurement group_id="O2" value="53"/>
                    <measurement group_id="O3" value="56"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Systemic reaction: moderate</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="22"/>
                    <measurement group_id="O2" value="37"/>
                    <measurement group_id="O3" value="30"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Systemic reaction: severe</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="7"/>
                    <measurement group_id="O3" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Fever: any</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="24"/>
                    <measurement group_id="O2" value="52"/>
                    <measurement group_id="O3" value="57"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Fever: 37.5-38.6°C</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="18"/>
                    <measurement group_id="O2" value="38"/>
                    <measurement group_id="O3" value="47"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Fever: 38.7-39.9°C</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6"/>
                    <measurement group_id="O2" value="14"/>
                    <measurement group_id="O3" value="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Fever: ≥ 40°C</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants Experiencing Local and Systemic Reactogenicity After Receiving Measles Vaccine</title>
        <description>Local reactions included erythema, pain, swelling, and induration. Systemic reactions included loss of appetite, crying, diarrhea, drowsiness, insomnia, irritability, and vomiting. The parents of the participants recorded all local reactions and systemic events on an individual safety diary form.</description>
        <time_frame>Up to 7 days after measles vaccination</time_frame>
        <population>Participants who received measles vaccine</population>
        <group_list>
          <group group_id="O1">
            <title>LJEV Then MV</title>
            <description>Received one dose of Live Japanese encephalitis vaccine SA 14-14-2 (LJEV) at 8 months of age, and one dose of measles vaccine (MV) one month later.</description>
          </group>
          <group group_id="O2">
            <title>LJEV and MV</title>
            <description>Received one dose of Live Japanese encephalitis vaccine SA 14-14-2 (LJEV) concurrently with one dose of measles vaccine (MV) at 9 months of age.</description>
          </group>
          <group group_id="O3">
            <title>MV Then LJEV</title>
            <description>Received one dose of measles vaccine (MV) at 9 months of age, followed by one dose of Live Japanese encephalitis vaccine SA 14-14-2 (LJEV) one month later.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants Experiencing Local and Systemic Reactogenicity After Receiving Measles Vaccine</title>
          <description>Local reactions included erythema, pain, swelling, and induration. Systemic reactions included loss of appetite, crying, diarrhea, drowsiness, insomnia, irritability, and vomiting. The parents of the participants recorded all local reactions and systemic events on an individual safety diary form.</description>
          <population>Participants who received measles vaccine</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="97"/>
                <count group_id="O2" value="236"/>
                <count group_id="O3" value="235"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Local reactions: any</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="19"/>
                    <measurement group_id="O2" value="44"/>
                    <measurement group_id="O3" value="61"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Local reactions: mild</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="15"/>
                    <measurement group_id="O2" value="42"/>
                    <measurement group_id="O3" value="50"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Local reactions: moderate</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                    <measurement group_id="O2" value="2"/>
                    <measurement group_id="O3" value="11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Local reactions: severe</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Systemic reactions: any</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="49"/>
                    <measurement group_id="O2" value="97"/>
                    <measurement group_id="O3" value="122"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Systemic reaction: mild</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="31"/>
                    <measurement group_id="O2" value="53"/>
                    <measurement group_id="O3" value="77"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Systemic reaction: moderate</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="13"/>
                    <measurement group_id="O2" value="37"/>
                    <measurement group_id="O3" value="42"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Systemic reaction: severe</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5"/>
                    <measurement group_id="O2" value="7"/>
                    <measurement group_id="O3" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Fever: any</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="31"/>
                    <measurement group_id="O2" value="52"/>
                    <measurement group_id="O3" value="64"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Fever: 37.5-38.6°C</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="21"/>
                    <measurement group_id="O2" value="38"/>
                    <measurement group_id="O3" value="52"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Fever: 38.7-39.9°C</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10"/>
                    <measurement group_id="O2" value="14"/>
                    <measurement group_id="O3" value="12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Fever: ≥ 40°C</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants Experiencing Unsolicited Adverse Events (AE)</title>
        <time_frame>Up to 7 days post-vaccination</time_frame>
        <population>Safety population</population>
        <group_list>
          <group group_id="O1">
            <title>LJEV Then MV</title>
            <description>Received one dose of Live Japanese encephalitis vaccine SA 14-14-2 (LJEV) at 8 months of age, and one dose of measles vaccine (MV) one month later.</description>
          </group>
          <group group_id="O2">
            <title>LJEV and MV</title>
            <description>Received one dose of Live Japanese encephalitis vaccine SA 14-14-2 (LJEV) concurrently with one dose of measles vaccine (MV) at 9 months of age.</description>
          </group>
          <group group_id="O3">
            <title>MV Then LJEV</title>
            <description>Received one dose of measles vaccine (MV) at 9 months of age, followed by one dose of Live Japanese encephalitis vaccine SA 14-14-2 (LJEV) one month later.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants Experiencing Unsolicited Adverse Events (AE)</title>
          <population>Safety population</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="100"/>
                <count group_id="O2" value="236"/>
                <count group_id="O3" value="235"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Any Adverse Event</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="35"/>
                    <measurement group_id="O2" value="43"/>
                    <measurement group_id="O3" value="79"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Related adverse event</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="4"/>
                    <measurement group_id="O3" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serious adverse event</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>1 month for serious adverse events and 7 days for non-serious adverse events</time_frame>
      <group_list>
        <group group_id="E1">
          <title>LJEV Then MV</title>
          <description>Received one dose of Live Japanese encephalitis vaccine SA 14-14-2 (LJEV) at 8 months of age, and one dose of measles vaccine (MV) one month later.</description>
        </group>
        <group group_id="E2">
          <title>LJEV and MV</title>
          <description>Received one dose of Live Japanese encephalitis vaccine SA 14-14-2 (LJEV) concurrently with one dose of measles vaccine (MV) at 9 months of age.</description>
        </group>
        <group group_id="E3">
          <title>MV Then LJEV</title>
          <description>Received one dose of measles vaccine (MV) at 9 months of age, followed by one dose of Live Japanese encephalitis vaccine SA 14-14-2 (LJEV) one month later.</description>
        </group>
      </group_list>
      <serious_events>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="236"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="235"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="100"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="236"/>
                <counts group_id="E3" subjects_affected="7" subjects_at_risk="235"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Amoebiasis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="100"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="236"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="235"/>
              </event>
              <event>
                <sub_title>Acute Gastroenteritis</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="100"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="236"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="235"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Pneumonia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="100"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="236"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="235"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Animal bite</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="236"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="235"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Complex Febrile Seizure</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="236"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="235"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Urinary tract infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="100"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="236"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="235"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Bronchial Asthma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="236"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="235"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="34" subjects_at_risk="100"/>
                <counts group_id="E2" subjects_affected="43" subjects_at_risk="236"/>
                <counts group_id="E3" subjects_affected="78" subjects_at_risk="235"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Viral conjunctivitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="236"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="235"/>
              </event>
              <event>
                <sub_title>Conjunctivitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="236"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="235"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Acute gastroenteritis</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="100"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="236"/>
                <counts group_id="E3" subjects_affected="8" subjects_at_risk="235"/>
              </event>
              <event>
                <sub_title>Intestinal parasitism</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="236"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="235"/>
              </event>
              <event>
                <sub_title>Oral candidiasis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="236"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="235"/>
              </event>
              <event>
                <sub_title>Stomatitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="100"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="236"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="235"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Immune system disorders</title>
            <event_list>
              <event>
                <sub_title>Bronchial asthma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="236"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="235"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Acute bronchitis</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="100"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="236"/>
                <counts group_id="E3" subjects_affected="5" subjects_at_risk="235"/>
              </event>
              <event>
                <sub_title>Acute otitis media</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="236"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="235"/>
              </event>
              <event>
                <sub_title>Acute Tonsillopharyngitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="236"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="235"/>
              </event>
              <event>
                <sub_title>Bacterial conjunctivitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="100"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="236"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="235"/>
              </event>
              <event>
                <sub_title>Cellulitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="236"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="235"/>
              </event>
              <event>
                <sub_title>Enteric fever</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="236"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="235"/>
              </event>
              <event>
                <sub_title>Pneumonia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="236"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="235"/>
              </event>
              <event>
                <sub_title>Roseola infantum</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="236"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="235"/>
              </event>
              <event>
                <sub_title>Systemic viral infection</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="100"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="236"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="235"/>
              </event>
              <event>
                <sub_title>Urinary tract infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="100"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="236"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="235"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Concussion</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="236"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="235"/>
              </event>
              <event>
                <sub_title>Infected wound</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="236"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="235"/>
              </event>
              <event>
                <sub_title>Insect bite</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="236"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="235"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Acute rhinitis</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="100"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="236"/>
                <counts group_id="E3" subjects_affected="10" subjects_at_risk="235"/>
              </event>
              <event>
                <sub_title>Upper respiratory tract infection</sub_title>
                <counts group_id="E1" subjects_affected="14" subjects_at_risk="100"/>
                <counts group_id="E2" subjects_affected="18" subjects_at_risk="236"/>
                <counts group_id="E3" subjects_affected="42" subjects_at_risk="235"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Atopic dermatitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="236"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="235"/>
              </event>
              <event>
                <sub_title>Dermatitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="236"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="235"/>
              </event>
              <event>
                <sub_title>Impetigo contagious</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="236"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="235"/>
              </event>
              <event>
                <sub_title>Maculo-papular lesions</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="236"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="235"/>
              </event>
              <event>
                <sub_title>Miliaria</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="236"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="235"/>
              </event>
              <event>
                <sub_title>Rash</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="236"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="235"/>
              </event>
              <event>
                <sub_title>Furuncle</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="236"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="235"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Surgical and medical procedures</title>
            <event_list>
              <event>
                <sub_title>Post-extraction hematoma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="236"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="235"/>
              </event>
              <event>
                <sub_title>Post-vaccination reaction</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="236"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="235"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Jorge Flores</name_or_title>
      <organization>PATH</organization>
      <phone>(202) 822-0033</phone>
      <email>jeflores@path.org</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

